MeMed: FDA Clears Pioneering MeMed BV Test Direct From Whole Blood Allowing Faster Time To Result And Broader Patient Access When Distinguishing Bacterial From Viral Infections

FDA Clears Pioneering MeMed BV Test Direct From Whole Blood Allowing Faster Time To Result And Broader Patient Access When Distinguishing Bacterial From Viral Infections

  • Opens up testing to decentralized settings including urgent care centers which see 100 million patient visits for potential infections in the US annually
  • Significant milestone towards making bacterial versus viral infection testing standard of care
  • Measurement of multiple low concentration proteins quickly in whole blood is notable new technological advance

TIRAT CARMEL, Israel; BOSTON, MA, 19 July, 2023 – MeMed, a leader in the emerging field of advanced host response technologies, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on whole blood samples on the point-of-need MeMed Key® analyzer to help healthcare providers distinguish between bacterial and viral infections in 15 minutes.

Through newly developed technology, MeMed BV on whole blood can accurately and quickly measure multiple proteins present in low concentrations from a small volume of whole blood. An earlier version of the test conducted on serum (cleared by the FDA in 2021) is being rolled out successfully in medical centers on the MeMed Key platform as well as on high throughput analyzers via partnerships with leading diagnostic companies.

This new version of MeMed BV retains the exceptional performance of its serum counterpart but eliminates the need for clotting and spinning, enabling MeMed to approach decentralized settings in the US, such as urgent care centers, where minimal handling and maintenance are essential.

Eran Eden, CEO of MeMed: “The FDA clearance of MeMed BV on whole blood is a significant milestone in our journey to make bacterial versus viral infection testing a standard of care. This enhancement to enable testing on whole blood allows for even easier use, faster results, and maintains the same level of performance, leading to improved patient care now being available across broader settings in the care continuum. The basis of physician prescription of unnecessary antibiotics is diagnostic uncertainty – is the patient presenting with a bacterial or a viral infection? The two are often clinically indistinguishable. By providing a rapid, reliable solution for differentiating between bacterial and viral infections, this test can help reduce the risk of unnecessary antibiotic prescriptions, one of the key drivers of antibiotic resistance.”

Dr Sridevi Devaraj, Medical Director of Clinical Chemistry and Point of Care Testing at Texas Children’s Hospital, said: “This enhancement to the MeMed BV test is an exciting development. The fact that the test can now be carried out directly on whole blood means minimal handling and a reduced burden in the clinical setting alongside a bacterial versus viral decision with shorter patient waiting times. I anticipate that this will enhance both patient and physician satisfaction.”

About MeMed
At MeMed, our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.
Follow and connect with MeMed via LinkedInTwitter, and Facebook.

MeMed Contacts:
Tal Avziz, VP Product & Marketing, MeMed
pr@me-med.com

Media relations contact:
Consilium Strategic Communications
MeMed@consilium-comms.com

Attachment

GlobeNewswire Distribution ID 1000830536

Major Shake-Up in World’s Passport Power Ranking

LONDON, July 18, 2023 (GLOBE NEWSWIRE) — Japan has been knocked off the top spot on the Henley Passport Index for the first time in five years and bumped into 3rd place, according to the latest ranking, which is based on exclusive and official data from the International Air Transport Association (IATA). Singapore is now officially the most powerful passport in the world, with its citizens able to visit 192 destinations out of 227 around the world visa-free. Germany, Italy, and Spain all move up into 2nd place with visa-free access to 190 destinations, and Japanese passport holders join those of six other nations — Austria, Finland, France, Luxembourg, South Korea, and Sweden — in 3rd place with access to 189 destinations without a prior visa.

The UK appears to have finally turned the corner after a six-year decline, jumping up two places on the latest ranking to 4th place — a position it last held in 2017. The US, on the other hand, continues its now decade-long slide down the index, plummeting a further two places to 8th spot with access to just 184 destinations visa-free. Both the UK and the US jointly held 1st place on the index nearly 10 years ago in 2014, but have been on a downward trajectory ever since. Afghanistan remains entrenched at the bottom of the Henley Passport Index, with a visa-free access score of just 27, followed by Iraq (score of 29), and Syria (score of 30) — the three weakest passports in the world.

The general trend over the history of the 18-year-old ranking has been towards greater travel freedom, with the average number of destinations travelers are able to access visa-free nearly doubling from 58 in 2006 to 109 in 2023. However, the global mobility gap between those at the top and bottom of the index is now wider than it has ever been, with top-ranked Singapore able to access 165 more destinations visa-free than Afghanistan.

Dr. Christian H. Kaelin, Chairman of Henley & Partners, says only eight countries worldwide have less visa-free access today than they did a decade ago, while others have been more successful in securing greater travel freedom for their citizens. “The UAE has added an impressive 107 destinations to its visa-free score since 2013, resulting in a massive leap of 44 places in the ranking over the past 10 years from 56th to 12th position. Of the countries sitting in the Top 10, the US has seen the smallest increase in its score, securing just 12 additional destinations. Singapore, by comparison, has increased its score by 25, pushing it up five places over the past 10 years to number one.”

Commenting in the Henley Global Mobility Report 2023 Q3, released today alongside the latest index, Greg Lindsay from Cornell Tech’s Jacobs Institute, says that from a purely mechanical perspective, “the story is a simple one — by more or less standing still, the US has fallen behind. While its absolute score has in fact risen over the last decade, the US has been steadily overtaken by rivals such as South Korea, Japan, and Singapore. America’s relentless slide down the rankings is a warning to its neighbor Canada and the rest of the Anglosphere as well.”

The links between visa-free access and openness

Henley & Partners has conducted exclusive new research into the relationship between a country’s openness to foreigners — how many nations it allows to cross its borders visa-free — and its own citizens’ travel freedom. The new Henley Openness Index ranks all 199 countries worldwide according to the number of nationalities they permit entry to without a prior visa.

The Top 20 ‘most open’ countries are all small island nations or African states, except for Cambodia. There are 12 countries that are completely open to all passports and four that don’t allow anyone in visa-free. While the correlation between a high openness score and high visa-free access score is not straightforward, it is notable that Singapore and South Korea — high climbers on the Henley Passport Index Top 10 over last decade, moving up from 6th and 7th respectively in 2013 to 1st and 3rd today — boast relatively high degrees of openness compared to the 5 countries with the biggest disparity between the travel freedom they enjoy, versus the visa-free access they provide to other nationalities. US, Canada, Australia, New Zealand and Japan have all either slid down the ranking or remained in the same place as their openness stagnates.

Prof. Peter J. Spiro, who holds the Charles Weiner Chair in international law at Temple University, says America’s extension of visa-free access is low, even by the standard of developed economies. “EU states grant visa-free privileges to more than twice the number of states than does the US. Processing delays, high refusal rates, and a reputation for disagreeable customer service are tarnishing the attractiveness of the US as a destination. Add to that the growing reputation of the US as ridden with gun violence and one can project a long-term trajectory in which US global standing further erodes.”

Read the full Press Release

Media Contact

Sarah Nicklin

Group Head of PR

sarah.nicklin@henleyglobal.com

Mobile: +27 72 464 8965

GlobeNewswire Distribution ID 1000830180

WHR Global Releases Ask an Expert 2023 Allowances & Per Diems Benchmark Report

WHR Global Shapes Clients’ Policies to Ensure Benefits Offerings Are Competitive in the Market

MILWAUKEE, July 17, 2023 (GLOBE NEWSWIRE) — WHR Global (WHR), a leader in the global employee relocation industry, announced the release of its international 2023 Allowances & Per Diems Benchmark Report called “Ask an Expert!”

At WHR, our mission is to provide clients with superior relocation services, and to do so, we need to be in tune with the global cost of living. To accomplish this, we created the Ask an Expert 2023 Allowances & Per Diems Benchmark Report, a comprehensive guide to understanding the true cost of living, not just in one city, but in many cities worldwide.

“Drawing from my own personal experience as a former expat residing in Switzerland, and a former relocation coordinator, I bring a deep understanding of the challenges and intricacies of international relocation,” said Sean Thrun, Strategic Initiatives Manager at WHR. “This benchmark report and firsthand knowledge equips WHR with the ability to provide valuable insights and guidance to mobility teams, enabling them to navigate the complexities of global assignments more effectively.”

The Report includes 8.8 million price submissions from 11,000 cities, and prices benchmarked by country include rental prices for 1 & 3 bedrooms both inside and outside of city centers, common utilities costs per month, local transportation, and more. Understanding the ground realities of cost of living helps relocation teams create scalable solutions and helps businesses have more productive moves, making the transition for employees smoother than ever.

The Report allows businesses to “check the pulse” of their allowances and per diems, whether they choose to administer fixed amounts globally, or variable by location. If global mobility teams find that the allowances and per diems offered to their employees are lower than the average for that country, contact WHR today for a free consultation, including a breakdown of the benchmark report by city.

Global mobility teams may use this Report, which covers 99 countries, to benchmark the following:

  • Monthly housing allowances for assignments & commuters,
  • Monthly utilities allowances for assignments & commuters,
  • Monthly transportation allowances for assignments & commuters,
  • Transportation per diems for preview and home finding trips, and
  • Meal per diems for preview and home finding trips.

Whether you are a relocation manager or a business leader, investing in the Ask an Expert 2023 Allowances & Per Diems Benchmark Report today can help you make the most informed decisions for your relocation budget and employee benefits policies.

See more data and download the complete 2023 Allowances & Per Diems Benchmark Report “Ask an Expert” here.

The Ask an Expert 2023 Allowances & Per Diems Benchmark is intended for informational purposes only.

About WHR Global

WHR Global (WHR) is a private, client-driven global relocation management company distinguished by its best-in-class service delivery and cutting-edge, proprietary technology. WHR has offices in the United States, Switzerland, and Singapore. With its 100% client retention rate for the past decade, WHR continues to position itself as the trusted leader in global employee relocation. WHR lives by its vision and passion for Advancing Lives Forward® and Making the Complex Simple. To learn more about WHR, visit https://www.whrg.com/, or follow on LinkedIn or Twitter.

Contact:
Sean Thrun, Strategic Initiatives Manager
+1-262-746-1314
Sean.Thrun@whrg.com

GlobeNewswire Distribution ID 8874927

Response to World Health Organization Reviews of Aspartame

BRUSSELS, Belgium, July 14, 2023 (GLOBE NEWSWIRE) — In response to two World Health Organization (WHO) evaluations of aspartame, one of the most thoroughly researched ingredients in the world, released today, the International Sweeteners Association (ISA) applauds the WHO’s reaffirmation of aspartame’s safety by its leading scientific body responsible for evaluating the safety of food additives, the Joint FAO/WHO Expert Committee on Food Additives (JECFA). These conclusions are consistent with the findings of over 90 global food safety agencies who have confirmed aspartame’s safety, including the European Food Safety Authority (EFSA), that has reviewed aspartame twice, and the US Food and Drug Administration (FDA).

“JECFA has once again reaffirmed aspartame’s safety after conducting a thorough, comprehensive and scientifically rigorous review,” said ISA Secretary General Frances Hunt-Wood. “Aspartame, like all low/no calorie sweeteners, when used as part of a balanced diet, provides consumers with choice to reduce sugar intake, a critical public health objective.”

As part of its comprehensive assessment, reconfirming the safety of aspartame, JECFA examined IARC’s conclusions and found no concern for human health. Importantly, IARC is not a food safety body and its 2B classification does not consider intake levels nor actual risk, making an IARC review far less comprehensive than the thorough reviews conducted by food safety bodies like JECFA and potentially confusing for consumers.

To put this in context, IARC’s 2B classification puts aspartame in the same category as kimchi and other pickled vegetables. IARC would be the first to say that they don’t suggest people should stop using kimchi at meals.

As part of an overall healthy diet and lifestyle, aspartame can be used to further public health objectives on sugar intake reduction and ultimately assist in weight and diabetes management, as well as with dental health.

For media enquiries, please contact the ISA PR agency:
media@sweeteners.org – Phone (24/7): +1 (833) 318-2430

www.sweeteners.org/news

GlobeNewswire Distribution ID 8874554

‫رد على مراجعات منظمة الصحة العالمية للأسبرتام

بروكسل، 14 يوليو 2023: ردًا على تقييمين تم إصدارهما اليوم لمنظمة الصحة العالمية (WHO) للأسبرتام، أحد أكثر المكونات التي قُتِلت بحثًا في العالم، تشيد الرابطة الدولية للمُحليِّات (ISA) بإعادة تأكيد المنظمة على سلامة الأسبرتام من خلال هيئتها العلمية الرائدة المسؤولة عن تقييم سلامة المُضافات الغذائية، وهي لجنة الخبراء المشتركة بين منظمة الأغذية والزراعة ومنظمة الصحة العالمية بشأن المُضافات الغذائية (JECFA). تتوافق هذه الاستنتاجات مع النتائج التي توصلت إليها أكثر من 90 وكالة عالمية لسلامة الأغذية أكدت على سلامة الأسبرتام، ومن بينها الهيئة الأوروبية لسلامة الأغذية  (EFSA) التي راجعت الأسبرتام مرتين وإدارة الغذاء والدواء الأمريكية إدارة الغذاء والدواء الأمريكية  (FDA).

“أعادت لجنة الخبراء المشتركة بين منظمة الأغذية والزراعة ومنظمة الصحة العالمية بشأن المُضافات الغذائية (JECFA) التأكيد مرة أخرى على سلامة الأسبرتام بعد إجراء مراجعة شاملة ودقيقة علميًا” حسب ما قالته الأمين العام للرابطة الدولية للمُحليِّات فرانسيس هانت-وود. حيث “يوفر الأسبرتام، مثل جميع المُحليِّات منخفضة السعرات/ الخالية من السعرات الحرارية عند استخدامه كجزء من نظام غذائي متوازن، للمستهلكين خيار تقليل مقدار كمية السكر التي يتناولونها، وهو هدف مهم متعلق بالصحة العامة”.

كجزء من تقييمها الشامل، لإعادة التأكيد على سلامة الأسبرتام، قامت لجنة الخبراء المشتركة بين منظمة الأغذية والزراعة ومنظمة الصحة العالمية بشأن المُضافات الغذائية (JECFA) بفحص استنتاجات الوكالة الدولية لبحوث السرطان (IARC) ولم تجد أي مخاوف متعلقة بصحة الإنسان. والأهم من ذلك، أن الوكالة الدولية لبحوث السرطان ليست هيئة سلامة أغذية ولا يأخذ تصنيفها 2B ممستويات الجرعة ولا المخاطر الفعلية في الحسبان، ما يجعل مراجعتها أقل شمولية بكثير من المراجعات الدقيقة التي أجرتها هيئات سلامة الأغذية مثل JEDFA وقد تكون أكثر تشتيتًا للمستهلكين.

لوضع هذا الأمر في سياق واضح، فإن تصنيف 2B للوكالة الدولية لبحوث السرطان (IARC) يضع الأسبرتام في الفئة نفسها مع الكيمتشي والخضراوات المخللة الأخرى. ستكون IARC أول من تقول بأنها لا تشير إلى أنه ينبغي للأشخاص التوقف عن استخدام الكيمتشي في الوجبات.

كجزء من نظام غذائي ونمط حياة صحيين بشكل عام، يمكن استخدام الأسبرتام لتعزيز أهداف الصحة العامة المتعلقة بتقليل كمية السكر التي يتم تناولها والمساعدة في النهاية على إدارة الوزن ومرض السكري، بالإضافة إلى الحفاظ على صحة الأسنان.

النهاية

للاستفسارات الإعلامية، يُرجى الاتصال بوكالة العلاقات العامة للرابطة الدولية للمُحليِّات:

media@sweeteners.org – هاتف (متاح على مدار الساعة طوال أيام الأسبوع): 318-2430 (833) 1+
www.sweeteners.org/news

GlobeNewswire Distribution ID 3597658